Intellia Therapeutics’ $690 Million Underwritten Public Offering

Goodwin Procter advised Intellia Therapeutics on the deal.Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced its $690 million underwritten public offering on the heels of releasing the first-ever clinical…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now